Multiple surgeries for glaucoma increased the risk of corneal edema in these patients, making lower-risk treatment ...

FDA limits COVID-19 vaccine access to high-risk individuals, reshaping public health policy amid ongoing debates on vaccine ...

Many patients later diagnosed with high-grade serous cancer had prior surgical or genetic testing opportunities that could ...

Under the second Trump administration, CMMI has published far more detail about peformance of Enhancing Oncology Model ...

Metabolic syndrome severity is a meaningful marker of chronic kidney disease risk even when patients do not have other major ...

Patients with acute respiratory failure who’ve been placed on a mechanical ventilator are less likely to be transferred to high-volume centers if they are uninsured, thus increasing their odds of ...

Chronic urticaria patients may have a higher risk of metabolic syndrome, with a pooled prevalence of 25.2% and an odds ratio ...

Medical school application and matriculation rates decreased for underrepresented racial and ethnic minorities in medicine ...

Ravi Vij, MD, MBA, discusses how measurable residual disease (MRD) testing is shaping treatment decisions in hematology and its potential to reduce costs and toxicity.

In the final clip, James D. Chalmers, MBChB, PhD, notes that while the FDA approval of brensocatib is a milestone, questions remain on optimal patient selection, long-term benefits, and further ...

Despite the findings, existing data around cardiovascular risk in chronic lymphocytic leukemia (CLL) are limited, and more ...

The definition of comprehensive non-small cell lung cancer (NSCLC) testing is rapidly evolving with new biomarkers and ...